Literature DB >> 25468698

Genotypic and phenotypic characterization of Staphylococcus aureus causing persistent and nonpersistent subclinical bovine intramammary infections during lactation or the dry period.

K A Veh1, R C Klein2, C Ster1, G Keefe3, P Lacasse4, D Scholl5, J-P Roy5, D Haine5, S Dufour5, B G Talbot1, A O B Ribon6, F Malouin7.   

Abstract

Staphylococcus aureus is a significant pathogen frequently causing persistent intramammary infections (IMI) in dairy cows. We compared some genotypic and phenotypic characteristics of 285 strains collected from quarter milk samples from cows with persistent and nonpersistent subclinical IMI across Canada. Variable number of tandem repeats typing was used to infer the persistence of the same S. aureus strain in 3 consecutive quarter milk samples collected at intervals of 3 wk during lactation or before and after dry-off. All first isolates of the series were used as the representative strains from persistent IMI and were compared with nonpersistent strains for the presence of genes seg, sen, sec, and tst as well as by spa typing. Biofilm production in vitro and hld-RNAIII expression levels were also quantified. The gene seg was associated with a reduction in the likelihood of the bacteria to cause a persistent IMI during lactation. Strains persisting through the dry period produced significantly more biofilm in vitro than strains that do not persist after calving. Also, we showed that strains expressing more hld were more likely to be nonpersistent during either lactation or through the dry period. Three spa types were predominant (t529, t267, and a novel type: t13401). In the strains studied, the spa type tbl 2645 was the most frequent, and 97.0% of the strains of this spa type carried both sen and seg. Strains from the spa type tbl 2645 were less likely to cause a persistent IMI in the dry period. Most (86.7%) of the strains of the novel spa type (t13401) were negative for seg, sen, or both and produced significantly more biofilm in vitro than tbl 2645 and t267. The present study expanded our current knowledge on the genotypic and phenotypic traits of S. aureus strains recovered from persistent and nonpersistent IMI in Canada.
Copyright © 2015 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Staphylococcus aureus; dairy cow; mastitis; persistence; subclinical

Mesh:

Substances:

Year:  2014        PMID: 25468698     DOI: 10.3168/jds.2014-8044

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  15 in total

1.  Characterisation of mecA gene negative Staphylococcus aureus isolated from bovine mastitis milk from Northern Germany.

Authors:  O H Sheet; N T Grabowski; G Klein; F Reich; A Abdulmawjood
Journal:  Folia Microbiol (Praha)       Date:  2019-03-19       Impact factor: 2.099

2.  Persistence of Staphylococcus spp. in milk from cows undergoing homeopathy to control subclinical mastitis.

Authors:  Elka Machado Ferreira; Letícia Castilho Romero; Maria de Lourdes Ribeiro de Souza da Cunha; Wilson Malagó Junior; Carlos Henrique Camargo; Waldomiro Barioni Júnior; Luiz Francisco Zafalon
Journal:  BMC Vet Res       Date:  2022-07-13       Impact factor: 2.792

3.  A C-type lectin from Bothrops jararacussu venom disrupts Staphylococcal biofilms.

Authors:  Raphael Contelli Klein; Mary Hellen Fabres-Klein; Leandro Licursi de Oliveira; Renato Neves Feio; François Malouin; Andréa de Oliveira Barros Ribon
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

4.  Characterization of a vraG Mutant in a Genetically Stable Staphylococcus aureus Small-Colony Variant and Preliminary Assessment for Use as a Live-Attenuated Vaccine against Intrammamary Infections.

Authors:  Julie Côté-Gravel; Eric Brouillette; Nataša Obradović; Céline Ster; Brian G Talbot; François Malouin
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

5.  In vitro antibiotic susceptibility and biofilm production of Staphylococcus aureus isolates recovered from bovine intramammary infections that persisted or not following extended therapies with cephapirin, pirlimycin or ceftiofur.

Authors:  Céline Ster; Valérie Lebeau; Julia Leclerc; Alexandre Fugère; Koui A Veh; Jean-Philippe Roy; François Malouin
Journal:  Vet Res       Date:  2017-09-21       Impact factor: 3.683

6.  Control of Staphylococcus aureus in dairy herds in a region with raw milk cheese production: farmers' attitudes, knowledge, behaviour and belief in self-efficacy.

Authors:  Marie-Eve Cousin; Maria Christina Härdi-Landerer; Verena Völk; Michèle Bodmer
Journal:  BMC Vet Res       Date:  2018-02-13       Impact factor: 2.741

7.  Antibiofilm and antibacterial effects of specific chitosan molecules on Staphylococcus aureus isolates associated with bovine mastitis.

Authors:  Abdelhamid Asli; Eric Brouillette; Céline Ster; Mariana Gabriela Ghinet; Ryszard Brzezinski; Pierre Lacasse; Mario Jacques; François Malouin
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

8.  Comparative genomics of Staphylococcus aureus associated with subclinical and clinical bovine mastitis.

Authors:  Lis S Rocha; Danielle M Silva; Mônica P Silva; Pedro Marcus P Vidigal; José Cleydson F Silva; Simony T Guerra; Márcio G Ribeiro; Tiago Antônio de O Mendes; Andréa de O B Ribon
Journal:  PLoS One       Date:  2019-08-07       Impact factor: 3.240

9.  Prevalence and characteristics of Livestock-Associated Methicillin-Resistant Staphylococcus aureus (LA-MRSA) isolated from chicken meat in the province of Quebec, Canada.

Authors:  Jocelyn Bernier-Lachance; Julie Arsenault; Valentine Usongo; Éric Parent; Josée Labrie; Mario Jacques; François Malouin; Marie Archambault
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

10.  High Production of LukMF' in Staphylococcus aureus Field Strains Is Associated with Clinical Bovine Mastitis.

Authors:  Jurriaan Hoekstra; Victor Rutten; Laura Sommeling; Tine van Werven; Mirlin Spaninks; Birgitta Duim; Lindert Benedictus; Gerrit Koop
Journal:  Toxins (Basel)       Date:  2018-05-15       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.